Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing

Rhea-AI Filing Summary

Morgan Stanley and Morgan Stanley Investment Management Inc. report significant beneficial ownership positions in Arbutus Biopharma Corp common shares. As of June 30, 2026, certain Morgan Stanley reporting units beneficially own 17,387,398 Arbutus common shares, representing 8.8% of the class, all with shared voting and dispositive power and no sole power.

Morgan Stanley Investment Management Inc. separately reports beneficial ownership of 17,122,142 Arbutus common shares, representing 8.7% of the class, also entirely with shared voting and dispositive power. The filing notes that it covers only specified Morgan Stanley reporting units and may exclude other units whose holdings are disaggregated under SEC Release No. 34-39538.

Key Figures

Morgan Stanley beneficial ownership: 17,387,398 shares Morgan Stanley ownership percentage: 8.8% MSIM beneficial ownership: 17,122,142 shares +2 more

5 metrics

Morgan Stanley beneficial ownership 17,387,398 shares Common shares of Arbutus Biopharma beneficially owned by Morgan Stanley reporting units

Morgan Stanley ownership percentage 8.8% Percent of Arbutus Biopharma common shares class reported by Morgan Stanley

MSIM beneficial ownership 17,122,142 shares Common shares of Arbutus Biopharma beneficially owned by Morgan Stanley Investment Management Inc.

MSIM ownership percentage 8.7% Percent of Arbutus Biopharma common shares class reported by MSIM

Event date 06/30/2026 Date associated with reported beneficial ownership levels

Key Terms

beneficially owned, shared voting power, shared dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 17,370,179.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 17,372,801.00"

parent holding company regulatory

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

Joint Filing Agreement regulatory

"EXHIBIT NO. EXHIBITS 99.1 Joint Filing Agreement"

FAQ

What ownership stake in Arbutus Biopharma (ABUS) does Morgan Stanley report?

Morgan Stanley reporting units beneficially own 17,387,398 Arbutus Biopharma common shares, representing 8.8% of the outstanding class as of June 30, 2026, all with shared voting and dispositive power.

How many Arbutus Biopharma (ABUS) shares does Morgan Stanley Investment Management hold?

Morgan Stanley Investment Management Inc. beneficially owns 17,122,142 Arbutus Biopharma common shares, or 8.7% of the class, with shared voting and shared dispositive power over all of these shares.

Does Morgan Stanley have sole voting power over any Arbutus Biopharma (ABUS) shares?

The filing reports 0 Arbutus Biopharma shares with sole voting power and 17,370,179 shares with shared voting power for Morgan Stanley, indicating all voting authority is shared for the reported units.

What type of SEC filing is this for Arbutus Biopharma (ABUS)?

This is an amended Schedule 13G/A, which discloses beneficial ownership of Arbutus Biopharma common shares by institutional investors, including Morgan Stanley and Morgan Stanley Investment Management Inc.

Are all Morgan Stanley units’ Arbutus Biopharma (ABUS) holdings included in this 13G/A?

No. The filing states it reflects securities beneficially owned by specified Morgan Stanley reporting units and may exclude holdings of other operating units disaggregated under SEC Release No. 34-39538.

Who signed the Schedule 13G/A for Arbutus Biopharma (ABUS) on behalf of Morgan Stanley?

The filing is signed by Claire Gordon, Authorized Signatory for Morgan Stanley, and Deidre A. Downes, Authorized Signatory for Morgan Stanley Investment Management Inc., both dated August 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 03:03 PM Accepted by SEC EDGAR 08/12/2026 - 03:02 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Arbutus Biopharma Corp

(Name of Issuer)

Common Shares

(Title of Class of Securities)

03879J100

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03879J100

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 17,370,179.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 17,372,801.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,387,398.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP Number(s): 03879J100

1

Names of Reporting Persons

Morgan Stanley Investment Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 17,122,142.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 17,122,142.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,122,142.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.7 %

12

Type of Reporting Person (See Instructions)

IA, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Arbutus Biopharma Corp
(b)	Address of issuer's principal executive offices: 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Investment Management Inc.
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 03879J100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 8.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/12/2026

Morgan Stanley Investment Management Inc.

Signature:	Deidre A. Downes
Name/Title:	Authorized Signatory, Morgan Stanley Investment Management Inc.
Date:	08/12/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).